Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study

about

Role of tenascin-C in articular cartilage.Urinary interleukin 22 binding protein as a marker of lupus nephritis in Egyptian children with juvenile systemic lupus erythematosus.Internal Affairs: Tenascin-C as a Clinically Relevant, Endogenous Driver of Innate Immunity.

P2860

Q39443859-7E9E173C-0DDF-4BFA-8AF5-EF46DB413FA2 Q47830590-556D0878-D031-4D0F-AF29-527D4399A3C0 Q49553693-5F3244B3-605F-4245-9B31-7E08E603B296

P2860

Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study

Item

http://www.wikidata.org/entity/Q36321563

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Serum tenascin-C discriminates ...... essive therapy: a cohort study

@ast

Serum tenascin-C discriminates ...... essive therapy: a cohort study

@en

type

Item

label

Serum tenascin-C discriminates ...... essive therapy: a cohort study

@ast

Serum tenascin-C discriminates ...... essive therapy: a cohort study

@en

prefLabel

Serum tenascin-C discriminates ...... essive therapy: a cohort study

@ast

Serum tenascin-C discriminates ...... essive therapy: a cohort study

@en

P1476

Serum tenascin-C discriminates ...... essive therapy: a cohort study

@en

P2093

Markéta Hušáková

http://www.w3.org/2001/XMLSchema#string

Michal Uher

http://www.w3.org/2001/XMLSchema#string

Radka Svobodová

http://www.w3.org/2001/XMLSchema#string

P2860

Tenascin-C in cardiovascular tissue remodeling: from development to inflammation and repair

Tenascins: regulation and putative functions during pathological stress

Tenascin-C is a useful marker for disease activity in myocarditis

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients.

Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus

Advances in tenascin-C biology.

Biomarkers in systemic lupus erythematosus: II. Markers of disease activity.

Biomarkers for systemic lupus erythematosus: a review and perspective.

Increased tenascin C and Toll-like receptor 4 levels in visceral adipose tissue as a link between inflammation and extracellular matrix remodeling in obesity.

P2888

s13075-015-0862-4

P304

341

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13075-015-0862-4

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284729836

http://www.w3.org/2001/XMLSchema#string

P6179

1037247235

http://www.w3.org/2001/XMLSchema#string

P698

26608564

http://www.w3.org/2001/XMLSchema#string

P932

4660660

http://www.w3.org/2001/XMLSchema#string

Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study

about

P2860

P2860

Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P6179

P698

P932